Summary

Europe Attention Deficit Hyperactivity Disorder Market is valued approximately USD 3.93 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 4.01% over the forecast period 2024-2032. Attention deficit hyperactivity disorder (ADHD) is a chronic neurodevelopmental condition affecting millions of children and adults. It is defined by inattention, hyperactivity, and impulsivity. People with ADHD may struggle to concentrate, pay attention, or remain still. They may be easily distracted, enthusiastic, or restless. ADHD is a complex disorder with unknown root cause. It is assumed to be a combination of hereditary and environmental influences. Furthermore, pharmaceutical treatment remains the primary technique for controlling ADHD symptoms. There is ongoing research into the development of new medications with improved efficacy and fewer side effects. Additionally, there is a trend toward the development of extended-release formulations to improve convenience and compliance. Thus, this trend is anticipated to support the Europe Attention Deficit Hyperactivity Disorder Market growth.

Moreover, the prevalence of ADHD is increasing globally, including in Europe. Factors such as changes in diagnostic criteria, awareness campaigns, and environmental factors contribute to this rise, resulting in a larger patient pool and increased demand for ADHD treatments. Also, governments in Europe are increasingly recognizing ADHD as a significant public health concern. This recognition often translates into initiatives aimed at improving diagnosis rates, access to treatment, and support services for individuals with ADHD, fostering market growth. Additionally, there's a greater acceptance of pharmacological interventions for ADHD, such as stimulant medications and non-stimulant alternatives, among healthcare professionals and patients. This acceptance expands the market for ADHD medications and therapies. However, high treatment costs, and stringent regulatory frameworks and approval processes for ADHD medications are expected to hinder the Europe Attention Deficit Hyperactivity Disorder Market growth during the forecast period 2024-2032.

The key countries considered for the Europe Attention Deficit Hyperactivity Disorder market study includes UK, Germany, France, Italy, Spain, and Rest of Europe. In 2023, Germany was the largest market in terms of revenue. the availability of a wide range of treatment options, including pharmacological interventions (such as stimulant and non-stimulant medications) and behavioral therapies, is fueling market growth. Pharmaceutical companies are continuously investing in research and development to introduce new and improved ADHD medications. Whereas, the United Kingdom is expected to grow with the highest CAGR during the forecast period 2024-2032.

Major market player included in this report are:
Novartis AG
Shire plc
Medice Arzneimittel Pütter GmbH & Co. KG
Company 4
Company 5
Company 6
Company 7
Company 8
Company 9
Company 10

The detailed segments and sub-segment of the market are explained below:

By Drug Type
Stimulants
Non-stimulants

By Demographics
Children
Adults

By Distribution Channel
Retail Pharmacy
Hospital Pharmacy
By Region:
Europe
UK
Germany
France
Spain
Italy
ROE

Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and Country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market

ページTOPに戻る

Table of Contents

Chapter 1. Europe Attention Deficit Hyperactivity Disorder Market Definition and Research Assumptions
1.1. Research Objective
1.2. Market Definition
1.3. Research Assumptions
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.3.3. Supply Side Analysis
1.3.3.1. Availability
1.3.3.2. Infrastructure
1.3.3.3. Regulatory Environment
1.3.3.4. Market Competition
1.3.3.5. Economic Viability (Consumer’s Perspective)
1.3.4. Demand Side Analysis
1.3.4.1. Regulatory frameworks
1.3.4.2. Technological Advancements
1.3.4.3. Environmental Considerations
1.3.4.4. Consumer Awareness & Acceptance
1.4. Estimation Methodology
1.5. Years Considered for the Study
1.6. Currency Conversion Rates

Chapter 2. Executive Summary
2.1. Europe Attention Deficit Hyperactivity Disorder Market Size & Forecast (2022- 2032)
2.2. Regional Summary
2.3. Segmental Summary
2.3.1. By Drug Type
2.3.2. By Demographics
2.3.3. By Distribution Channel
2.4. Key Trends
2.5. Recession Impact
2.6. Analyst Recommendation & Conclusion
Chapter 3. Europe Attention Deficit Hyperactivity Disorder Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
Chapter 4. Europe Attention Deficit Hyperactivity Disorder Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Europe Attention Deficit Hyperactivity Disorder Market Size & Forecasts by Drug Type 2022-2032
5.1. Stimulants
5.2. Non-stimulants
Chapter 6. Europe Attention Deficit Hyperactivity Disorder Market Size & Forecasts by Demographics 2022-2032
6.1. Children
6.2. Adults
Chapter 7. Europe Attention Deficit Hyperactivity Disorder Market Size & Forecasts by Distribution Channel 2022-2032
7.1. Retail Pharmacy
7.2. Hospital Pharmacy
Chapter 8. Europe Attention Deficit Hyperactivity Disorder Market Size & Forecasts by Country 2022-2032
8.1. U.K. Attention Deficit Hyperactivity Disorder Market
8.1.1. Drug Type breakdown size & forecasts, 2022-2032
8.1.2. Demographics breakdown size & forecasts, 2022-2032
8.1.3. Distribution Channel breakdown size & forecasts, 2022-2032
8.2. Germany Attention Deficit Hyperactivity Disorder Market
8.3. France Attention Deficit Hyperactivity Disorder Market
8.4. Spain Attention Deficit Hyperactivity Disorder Market
8.5. Italy Attention Deficit Hyperactivity Disorder Market
8.6. Rest of Europe Attention Deficit Hyperactivity Disorder Market
Chapter 9. Competitive Intelligence
9.1. Key Company SWOT Analysis
9.1.1. Company 1
9.1.2. Company 2
9.1.3. Company 3
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. Novartis AG
9.3.1.1. Key Information
9.3.1.2. Overview
9.3.1.3. Financial (Subject to Data Availability)
9.3.1.4. Product Summary
9.3.1.5. Market Strategies
9.3.2. Shire plc
9.3.3. Medice Arzneimittel Pütter GmbH & Co. KG
9.3.4. Company 4
9.3.5. Company 5
9.3.6. Company 6
9.3.7. Company 7
9.3.8. Company 8
9.3.9. Company 9
9.3.10. Company 10
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes